

Piotr Rutkowski

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6664118/piotr-rutkowski-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

278
papers

32,143
citations

62
h-index

178
g-index

344
ext. papers

40,767
ext. citations

6.5
avg, IF

6.64
L-index

#	Paper	IF	Citations
278	Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for V600-Mutant Unresectable or Metastatic Melanoma.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101601	2.2	10
277	Treatment of Locally Advanced Merkel Cell Carcinoma-A Multi-Center Study.. <i>Cancers</i> , 2022 , 14,	6.6	2
276	Efficacy of immunotherapy beyond RECIST progression in advanced melanoma: a real-world evidence.. <i>Cancer Immunology, Immunotherapy</i> , 2022 , 1	7.4	0
275	Stereotactic radiotherapy for soft tissue and bone sarcomas: real-world evidence.. <i>Therapeutic Advances in Medical Oncology</i> , 2022 , 14, 17588359211070646	5.4	1
274	Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047). <i>Journal of Clinical Oncology</i> , 2022 , 40, 360385-360385	2.2	1
273	Prognostic and predictive value of Tblockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.. <i>European Journal of Cancer</i> , 2022 , 165, 97-112	7.5	0
272	Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.. <i>Lancet, The</i> , 2022 ,	40	18
271	The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021.. <i>Journal of Translational Medicine</i> , 2022 , 20, 200	8.5	
270	Ultrasound-Guided Trans-Uterine Cavity Core Needle Biopsy of Uterine Myometrial Tumors to Differentiate Sarcoma from a Benign LesionDescription of the Method and Review of the Literature. <i>Diagnostics</i> , 2022 , 12, 1348	3.8	1
269	Correlation of Immunological and Molecular Profiles with Response to Crizotinib in Alveolar Soft Part Sarcoma: An Exploratory Study Related to the EORTC 90101 [CREATE]Trial. <i>International Journal of Molecular Sciences</i> , 2022 , 23, 5689	6.3	
268	Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patients. <i>Melanoma Research</i> , 2021 , 31, 49-57	3.3	0
267	545 A phase 2 study of retifanlimab in patients with advanced or metastatic merkel cell carcinoma (MCC) (POD1UM-201) 2021 , 9, A574-A575		0
266	Melanoma-derived small extracellular vesicles induce lymphangiogenesis and metastasis through an NGFR-dependent mechanism.. <i>Nature Cancer</i> , 2021 , 2, 1387-1405	15.4	7
265	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2021 , JCO2102229	2.2	39
264	Mutational landscape of primary and recurrent Ewing sarcoma.. <i>Wspolczesna Onkologia</i> , 2021 , 25, 241-248		0
263	Treatment of Metastatic Gastrointestinal Stromal Tumors (GIST): A Focus on Older Patients. <i>Drugs and Aging</i> , 2021 , 38, 375-396	4.7	1
262	First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in Poland. <i>Immunotherapy</i> , 2021 , 13, 297-307	3.8	3

261	Morbidity and Outcomes After Distal Pancreatectomy for Primary Retroperitoneal Sarcoma: An Analysis by the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group. <i>Annals of Surgical Oncology</i> , 2021 , 28, 6882-6889	3.1	2
260	Biological Heterogeneity of Chondrosarcoma: From (Epi) Genetics through Stemness and Deregulated Signaling to Immunophenotype. <i>Cancers</i> , 2021 , 13,	6.6	2
259	Reply to E. Hindi. <i>Journal of Clinical Oncology</i> , 2021 , 39, 944-946	2.2	
258	Analysis of Differentiation Changes and Outcomes at Time of First Recurrence of Retroperitoneal Liposarcoma by Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). <i>Annals of Surgical Oncology</i> , 2021 , 28, 7854-7863	3.1	3
257	Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. <i>Cancer</i> , 2021 , 127, 2934-2942	6.4	11
256	Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group. <i>Annals of Surgical Oncology</i> , 2021 , 28, 7873-7888	3.1	15
255	Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Apocrine and Eccrine Differentiation. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	5
254	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 655-664	21.7	9
253	Chondrosarcoma-from Molecular Pathology to Novel Therapies. <i>Cancers</i> , 2021 , 13,	6.6	8
252	Feasibility and Long-Term Efficacy of PEComa Treatment-20 Years of Experience. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	4
251	Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma. <i>Journal of Dermatological Treatment</i> , 2021 , 1-7	2.8	0
250	Overall survival benefit from tebentafusp in patients with best response of progressive disease.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9509-9509	2.2	2
249	Hyperpolarized ¹³ C tracers: Technical advancements and perspectives for clinical applications. <i>Biocybernetics and Biomedical Engineering</i> , 2021 , 41, 1466-1466	5.7	1
248	Treatment beyond progression with immune checkpoint inhibitors in advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e21541-e21541	2.2	
247	Systemic treatment of patients with inoperable and metastatic Merkel cell carcinoma: A multicenter study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e21521-e21521	2.2	
246	Comparison of the efficacy and toxicity of anti-PD-1 monoclonal antibodies (nivolumab versus pembrolizumab) in treatment of patients with metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e21514-e21514	2.2	0
245	Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9503-9503	2.2	49
244	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 643-654	21.7	58

243	ASO Visual Abstract: An Analysis of 'Differentiation' Changes and Outcomes at the 'First' Recurrence of Retroperitoneal Liposarcoma by the Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). <i>Annals of Surgical Oncology</i> , 2021 , 28, 490-491	3.1	1
242	Merkel Cell Carcinoma from Molecular Pathology to Novel Therapies. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	6
241	The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practice. <i>European Journal of Surgical Oncology</i> , 2021 , 47, 1191-1195	3.6	2
240	Defining the role of neoadjuvant systemic therapy in high-risk retroperitoneal sarcoma: A multi-institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. <i>Cancer</i> , 2021 , 127, 729-738	6.4	7
239	Has the Outcome for Patients Who Undergo Resection of Primary Retroperitoneal Sarcoma Changed Over Time? A Study of Time Trends During the Past 15 years. <i>Annals of Surgical Oncology</i> , 2021 , 28, 1700-1709	3.1	12
238	New Therapies in Advanced Cutaneous Malignancies: Conclusions 2021 , 441-448		0
237	Detection of Melanoma Cells in Lymphatic Drainage (LD) After Lymph Nodes Dissection Via Nested RT-PCR Analysis of Molecular Melanocytic Markers. <i>Methods in Molecular Biology</i> , 2021 , 2265, 377-384	1.4	
236	Neoadjuvant and Adjuvant Therapies of Melanoma 2021 , 401-415		
235	Peripheral Blood Cells from Patients with Hodgkin's and Diffuse Large B Cell Lymphomas May Be a Better Source of Candidate Diagnostic miRNAs Than Circulating miRNAs. <i>BioMed Research International</i> , 2021 , 2021, 3212878	3	
234	Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy. <i>Oncologist</i> , 2021 , 26, e639-e649	5.7	11
233	Radiotherapy in the Management of Pediatric and Adult Osteosarcomas: A Multi-Institutional Cohort Analysis. <i>Cells</i> , 2021 , 10,	7.9	1
232	The Management of Radiation-Induced Sarcomas: A Cohort Analysis from a Sarcoma Tertiary Center. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
231	Combined Preoperative Hypofractionated Radiotherapy With Doxorubicin-Ifosfamide Chemotherapy in Marginally Resectable Soft Tissue Sarcomas: Results of a Phase 2 Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 110, 1053-1063	4	3
230	Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study. <i>European Journal of Surgical Oncology</i> , 2021 , 47, 2173-2181	3.6	1
229	Complete pathological response to neoadjuvant treatment is associated with better survival outcomes in patients with soft tissue sarcoma: Results of a retrospective multicenter study. <i>European Journal of Surgical Oncology</i> , 2021 , 47, 2166-2172	3.6	9
228	TP53 in Biology and Treatment of Osteosarcoma. <i>Cancers</i> , 2021 , 13,	6.6	5
227	Efficacy of Sirolimus Treatment in PEComa-10 Years of Practice Perspective. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
226	What is the best front-line approach in patients with desmoid fibromatosis? - A retrospective analysis from a reference center. <i>European Journal of Surgical Oncology</i> , 2021 , 47, 2602-2608	3.6	0

225	Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3128-3139	2.2	12
224	Longitudinal prognostication in retroperitoneal sarcoma survivors: Development and external validation of two dynamic nomograms. <i>European Journal of Cancer</i> , 2021 , 157, 291-300	7.5	3
223	Mechanisms of Resistance to Targeted Therapies in Skin Cancers 2021 , 357-384		
222	Postoperative Morbidity After Resection of Recurrent Retroperitoneal Sarcoma: A Report from the Transatlantic Australasian RPS Working Group (TARPSWG). <i>Annals of Surgical Oncology</i> , 2021 , 28, 2705-2714	2.1	6
221	Impact of COVID-19 on anxiety levels among patients with cancer actively treated with systemic therapy. <i>ESMO Open</i> , 2020 , 5, e000970	6	43
220	Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial. <i>European Journal of Cancer</i> , 2020 , 133, 94-103	7.5	8
219	A durable complete response to immunotherapy in a patient with metastatic alveolar soft part sarcoma. <i>Tumori</i> , 2020 , 106, NP9-NP13	1.7	3
218	Coronavirus Disease (COVID-19) Outbreak: Hypofractionated Radiotherapy in Soft Tissue Sarcomas as a Valuable Option in the Environment of Limited Medical Resources and Demands for Increased Protection of Patients. <i>Frontiers in Oncology</i> , 2020 , 10, 993	5.3	7
217	Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma 2020 , 8,		19
216	Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients - Real world evidence. <i>Advances in Medical Sciences</i> , 2020 , 65, 316-323	2.8	6
215	Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2020 , 395, 1835-1844	4.0	204
214	Quality of treatment and surgical approach for rectal gastrointestinal stromal tumour (GIST) in a large European cohort. <i>European Journal of Surgical Oncology</i> , 2020 , 46, 1124-1130	3.6	15
213	Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. <i>Cancer</i> , 2020 , 126, 2637-2647	6.4	31
212	Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. <i>Lancet Oncology, The</i> , 2020 , 21, 935-946	21.7	101
211	TP53-Deficient Angiosarcoma Expression Profiling in Rat Model. <i>Cancers</i> , 2020 , 12,	6.6	2
210	Targeted Therapy in Melanoma and Mechanisms of Resistance. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	35
209	Cell-free DNA V600E measurements during BRAF inhibitor therapy of metastatic melanoma: long-term analysis. <i>Tumori</i> , 2020 , 300891619900928	1.7	7
208	Signatures of circulating microRNA in four sarcoma subtypes. <i>Journal of Cancer</i> , 2020 , 11, 874-882	4.5	9

207	BRAF inhibition curtails IFN-gamma-inducible PD-L1 expression and upregulates the immunoregulatory protein galectin-1 in melanoma cells. <i>Molecular Oncology</i> , 2020 , 14, 1817-1832	7.9	8
206	Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy 2020 , 8,		13
205	Mutation profile of primary subungual melanomas in Caucasians. <i>Oncotarget</i> , 2020 , 11, 2404-2413	3.3	4
204	Systemic Treatment for Advanced and Metastatic Malignant Peripheral Nerve Sheath Tumors-A Sarcoma Reference Center Experience. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	3
203	Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 519-527	13.4	148
202	Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials. <i>European Journal of Cancer</i> , 2020 , 125, 114-120	7.5	29
201	KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. <i>Future Oncology</i> , 2020 , 16, 4429-4438	3.6	23
200	Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study. <i>ESMO Open</i> , 2020 , 5,	6	8
199	Five-Year Outcomes With Nivolumab in Patients With Wild-Type Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3937-3946	2.2	39
198	Malignant peripheral nerve sheath tumors - Outcomes and prognostic factors based on the reference center experience. <i>Surgical Oncology</i> , 2020 , 35, 276-284	2.5	1
197	Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study 2020 , 8,		13
196	The Landmark Series: Systemic Therapy for Resectable Gastrointestinal Stromal Tumors. <i>Annals of Surgical Oncology</i> , 2020 , 27, 3659-3671	3.1	5
195	Epithelioid Sarcoma-From Genetics to Clinical Practice. <i>Cancers</i> , 2020 , 12,	6.6	11
194	Hypofractionated Radiotherapy in Locally Advanced Myxoid Liposarcomas of Extremities or Trunk Wall: Results of a Single-Arm Prospective Clinical Trial. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	6
193	SOX10 is as specific as S100 protein in detecting metastases of melanoma in lymph nodes and is recommended for sentinel lymph node assessment. <i>European Journal of Cancer</i> , 2020 , 137, 175-182	7.5	7
192	The clinical prognostic factors and treatment outcomes of adult patients with Ewing sarcoma. <i>International Journal of Clinical Oncology</i> , 2020 , 25, 2006-2014	4.2	3
191	Neoadjuvant Treatment Options in Soft Tissue Sarcomas. <i>Cancers</i> , 2020 , 12,	6.6	5
190	Molecular Biology of Osteosarcoma. <i>Cancers</i> , 2020 , 12,	6.6	94

189	Multimodal Treatment of Advanced Mucosal Melanoma in the Era of Modern Immunotherapy. <i>Cancers</i> , 2020 , 12,	6.6	7
188	Clinicopathological Features and Prognostic Factors of Primary Acral Melanomas in Caucasians. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	4
187	Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2020 , 21, 1366-1377	21.7	84
186	Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3925-3936	2.2	78
185	BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma. <i>Melanoma Research</i> , 2020 , 30, 465-471	3.3	7
184	An update on the safety of nivolumab for the treatment of advanced melanoma. <i>Expert Opinion on Drug Safety</i> , 2020 , 19, 409-421	4.1	4
183	Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , 2019 , 119, 168-178	7.5	32
182	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2019 , 381, 1535-1546	59.2	1260
181	Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600E/K-mutant advanced or metastatic melanoma. <i>European Journal of Cancer</i> , 2019 , 109, 61-69	7.5	18
180	Molecular Comparison of Imatinib-Naïve and Resistant Gastrointestinal Stromal Tumors: Differentially Expressed microRNAs and mRNAs. <i>Cancers</i> , 2019 , 11,	6.6	5
179	Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2019 , 381, 626-636	59.2	489
178	Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2019 , 116, 148-157	7.5	42
177	Natural history of well-differentiated liposarcoma of the extremity compared to patients treated with surgery. <i>Surgical Oncology</i> , 2019 , 29, 84-89	2.5	6
176	Defining Rupture in Gastrointestinal Stromal Tumor: Semantics and Prognostic Value. <i>Annals of Surgical Oncology</i> , 2019 , 26, 2304-2305	3.1	4
175	Defining Tumor Rupture in Gastrointestinal Stromal Tumor. <i>Annals of Surgical Oncology</i> , 2019 , 26, 1669-1675	3.6	29
174	Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and mutation. <i>Journal of Experimental Medicine</i> , 2019 , 216, 1061-1070	16.6	67
173	Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. <i>Journal of Clinical Oncology</i> , 2019 , 37, 867-875	2.2	135
172	Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram from TARPSWG. <i>Clinical Cancer Research</i> , 2019 , 25, 2664-2671	12.9	40

171	Outcome of First-Line Systemic Treatment for Unresectable Conventional, Dedifferentiated, Mesenchymal, and Clear Cell Chondrosarcoma. <i>Oncologist</i> , 2019 , 24, 110-116	5.7	23
170	ASO Author Reflections: The Importance of Defining Tumor Rupture in GIST Before Research. <i>Annals of Surgical Oncology</i> , 2019 , 26, 684-685	3.1	
169	Prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in patients with advanced gastrointestinal stromal tumors treated with sunitinib after imatinib failure. <i>Oncology Letters</i> , 2019 , 18, 3373-3380	2.6	2
168	Basal cell carcinoma. Diagnostic and therapeutic recommendations of Polish Dermatological Society. <i>Przegląd Dermatologiczny</i> , 2019 , 106, 107-126	0.4	3
167	Squamous cell carcinoma and Merkel-cell carcinoma. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. <i>Przegląd Dermatologiczny</i> , 2019 , 106, 127-149	0.4	1
166	NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial. <i>Lancet Oncology, The</i> , 2019 , 20, 1148-1159	21.7	148
165	Comparison of seventh and eighth edition of AJCC staging system in melanomas at locoregional stage. <i>World Journal of Surgical Oncology</i> , 2019 , 17, 129	3.4	7
164	Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , 2019 , 121, 144-153	7.5	19
163	Principles of prophylactic and therapeutic management of skin toxicity during treatment with checkpoint inhibitors. <i>Postępy Dermatologii i Alergologii</i> , 2019 , 36, 382-391	1.5	19
162	Health-related quality of life in patients with fully resected BRAF mutation-positive melanoma receiving adjuvant vemurafenib. <i>European Journal of Cancer</i> , 2019 , 123, 155-161	7.5	2
161	Functional outcome of surgical treatment of adults with extremity osteosarcoma after megaprosthesis reconstruction-single-center experience. <i>Journal of Orthopaedic Surgery and Research</i> , 2019 , 14, 346	2.8	11
160	Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. <i>Lancet Oncology, The</i> , 2019 , 20, 1719-1729	21.7	74
159	Merkel cell carcinoma (MCC) [neuroendocrine skin cancer. <i>Nowotwory</i> , 2019 , 69, 111-116	0.5	4
158	Molecular biology of sarcoma 2019 , 14, 307-330		3
157	Why do we need a new BRAF-MEK inhibitor combination in melanoma? 2019 , 15, 115-119		2
156	Mucosal melanoma [clinical presentation and treatment based on a case series 2019 , 15, 223-230		2
155	Pigmented/melanocytic malignant perivascular epithelioid cell tumor with TFE3-SFPQ(PSF) rearrangement - a challenging diagnosis of PEComa family of tumors. <i>Polish Journal of Pathology</i> , 2019 , 70, 317-322	0.9	1
154	Quiz. What is your diagnosis?. <i>Polish Journal of Pathology</i> , 2019 , 70, 232-233	0.9	

153	Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice. <i>Targeted Oncology</i> , 2019 , 14, 729-742	5	9
152	Immune checkpoint inhibitors therapy in older patients (≥70 years) with metastatic melanoma: a multicentre study. <i>Postepy Dermatologii I Alergologii</i> , 2019 , 36, 566-571	1.5	8
151	An open-label, multicentre safety study of vemurafenib in patients with BRAF-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. <i>European Journal of Cancer</i> , 2019 , 107, 175-185	7.5	7
150	Rational combination of cancer immunotherapy in melanoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019 , 474, 433-447	5.1	6
149	Radiotherapy for retroperitoneal liposarcoma: A report from the Transatlantic Retroperitoneal Sarcoma Working Group. <i>Cancer</i> , 2019 , 125, 1290-1300	6.4	33
148	Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial. <i>JAMA Oncology</i> , 2019 , 5, 187-194	13.4	173
147	ECCO essential requirements for quality cancer care: Melanoma. <i>Critical Reviews in Oncology/Hematology</i> , 2018 , 122, 164-178	7	24
146	Adjuvant vemurafenib in resected, BRAF mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 510-520	21.7	123
145	Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial. <i>Lancet Respiratory Medicine, the</i> , 2018 , 6, 431-441	35.1	87
144	Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. <i>New England Journal of Medicine</i> , 2018 , 378, 1789-1801	59.2	918
143	Risk stratification of sentinel node-positive melanoma patients defines surgical management and adjuvant therapy treatment considerations. <i>European Journal of Cancer</i> , 2018 , 96, 25-33	7.5	50
142	Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial. <i>European Journal of Surgical Oncology</i> , 2018 , 44, 1384-1390	3.6	47
141	Differences in recurrence and survival of extremity liposarcoma subtypes. <i>European Journal of Surgical Oncology</i> , 2018 , 44, 1391-1397	3.6	16
140	Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series. <i>JAMA Oncology</i> , 2018 , 4, e180219	13.4	46
139	Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07). <i>Cancer</i> , 2018 , 124, 1449-1454	6.4	21
138	Treatment outcomes in older patients with advanced gastrointestinal stromal tumor (GIST). <i>Journal of Geriatric Oncology</i> , 2018 , 9, 520-525	3.6	6
137	The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE'. <i>European Journal of Cancer</i> , 2018 , 94, 156-167	7.5	27
136	Postoperative Morbidity After Radical Resection of Primary Retroperitoneal Sarcoma: A Report From the Transatlantic RPS Working Group. <i>Annals of Surgery</i> , 2018 , 267, 959-964	7.8	78

135	Immunotherapy of melanoma. <i>Wspolczesna Onkologia</i> , 2018 , 22, 61-67	1	53
134	Coordinated expression and genetic polymorphisms in Grainyhead-like genes in human non-melanoma skin cancers. <i>BMC Cancer</i> , 2018 , 18, 23	4.8	6
133	Blood neutrophil-to-lymphocyte ratio is associated with prognosis in advanced gastrointestinal stromal tumors treated with imatinib. <i>Tumori</i> , 2018 , 104, 415-422	1.7	8
132	Advances in the management of giant cell tumor of bone: current options and future challenges. <i>Expert Opinion on Orphan Drugs</i> , 2018 , 6, 553-561	1.1	0
131	MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 916-929	21.7	83
130	Value of planar lymphoscintigraphy (PL) versus SPECT/CT in evaluation of sentinel lymph node in trunk melanoma - one center, large series retrospective study. <i>Nuclear Medicine Review</i> , 2018 , 21, 79-84	0.3	11
129	Candidate diagnostic miRNAs that can detect cancer in prostate biopsy. <i>Prostate</i> , 2018 , 78, 178-185	4.2	17
128	Management of the "Other" retroperitoneal sarcomas. <i>Journal of Surgical Oncology</i> , 2018 , 117, 79-86	2.8	9
127	Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. <i>Oncologist</i> , 2018 , 23, 62-70	5.7	42
126	Is the Surgical Margin in Gastrointestinal Stromal Tumors Different?. <i>Visceral Medicine</i> , 2018 , 34, 347-352	2.4	4
125	Gastrointestinal Stromal Tumors. <i>Visceral Medicine</i> , 2018 , 34, 376-379	2.4	2
124	Genetic polymorphisms may influence the vertical growth rate of melanoma. <i>Journal of Cancer</i> , 2018 , 9, 3078-3083	4.5	2
123	Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 1480-1492	21.7	680
122	IDH1/2 Mutations Predict Shorter Survival in Chondrosarcoma. <i>Journal of Cancer</i> , 2018 , 9, 998-1005	4.5	30
121	High baseline neutrophil-to-lymphocyte ratio predicts worse outcome in patients with metastatic BRAF-positive melanoma treated with BRAF and MEK inhibitors. <i>Melanoma Research</i> , 2018 , 28, 435-441	3.3	6
120	Surgical management of metastatic gastrointestinal stromal tumour. <i>European Journal of Surgical Oncology</i> , 2018 , 44, 1295-1300	3.6	7
119	Post-relapse outcomes after primary extended resection of retroperitoneal sarcoma: A report from the Trans-Atlantic RPS Working Group. <i>Cancer</i> , 2017 , 123, 1971-1978	6.4	68
118	Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 435-445	21.7	240

117	Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. <i>European Journal of Cancer</i> , 2017 , 82, 45-55	7.5	114
116	Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate - The impact of fibrosarcomatous transformation. <i>European Journal of Surgical Oncology</i> , 2017 , 43, 1134-1141	3.6	38
115	Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology</i> , 2017 , 18, 611-622	21.7	306
114	Novel methods of image description and ensemble of classifiers in application to mammogram analysis. <i>Expert Systems With Applications</i> , 2017 , 81, 67-78	7.8	18
113	Dermatofibrosarcoma protuberans and gastrointestinal stromal tumor as models for targeted therapy in soft tissue sarcomas. <i>Expert Review of Anticancer Therapy</i> , 2017 , 17, 1107-1116	3.5	7
112	Treatment results of adult patients with primary bone tumours of the humerus with the use of the oncological modular endoprosthesis. <i>Wspolczesna Onkologia</i> , 2017 , 21, 228-231	1	0
111	The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST). <i>Wspolczesna Onkologia</i> , 2017 , 21, 285-289	1	7
110	Treatment of gastrointestinal stromal tumours in paediatric and young adult patients with sunitinib: a multicentre case series. <i>BMC Cancer</i> , 2017 , 17, 717	4.8	8
109	Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3807-3814	2.2	264
108	Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1713-1720	2.2	88
107	Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. <i>New England Journal of Medicine</i> , 2017 , 377, 1824-1835	59.2	1178
106	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2017 , 377, 1345-1356	59.2	2030
105	Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial. <i>European Journal of Cancer</i> , 2017 , 87, 147-163	7.5	74
104	Health-related quality of life results from the phase III CheckMate 067 study. <i>European Journal of Cancer</i> , 2017 , 82, 80-91	7.5	55
103	Long-term results of therapy with sunitinib in metastatic alveolar soft part sarcoma. <i>Tumori</i> , 2017 , 103, 231-235	1.7	20
102	Abstract CT075: Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients with advanced melanoma (CheckMate 067) 2017 ,		26
101	Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9524-9524	2.2	14
100	Combined Therapy of Gastrointestinal Stromal Tumors. <i>Surgical Oncology Clinics of North America</i> , 2016 , 25, 735-59	2.7	18

99	Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity. <i>European Journal of Cancer</i> , 2016 , 55, 111-21	7.5	70
98	Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial. <i>BMC Cancer</i> , 2016 , 16, 22	4.8	43
97	The safety of regorafenib for the treatment of gastrointestinal stromal tumors. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 105-16	4.1	14
96	Cutaneous melanoma guidelines for diagnostics and therapy in 2016. <i>Przegląd Dermatologiczny</i> , 2016 , 1, 1-18	0.4	
95	Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS): A Report on 1007 Patients From the Multi-institutional Collaborative RPS Working Group. <i>Annals of Surgery</i> , 2016 , 263, 1002-9	7.8	242
94	External validation of a multi-institutional retroperitoneal sarcoma nomogram. <i>Cancer</i> , 2016 , 122, 1417-24	7.4	58
93	Denosumab treatment of inoperable or locally advanced giant cell tumor of bone. <i>Oncology Letters</i> , 2016 , 12, 4312-4318	2.6	20
92	Effects of time interval between primary melanoma excision and sentinel node biopsy on positivity rate and survival. <i>European Journal of Cancer</i> , 2016 , 67, 164-173	7.5	21
91	Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone. <i>Clinical Sarcoma Research</i> , 2016 , 6, 15	2.5	64
90	Nivolumab in previously untreated melanoma without BRAF mutation. <i>New England Journal of Medicine</i> , 2015 , 372, 320-30	59.2	3809
89	KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence. <i>Journal of Clinical Oncology</i> , 2015 , 33, 634-42	2.2	104
88	Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. <i>European Journal of Cancer</i> , 2015 , 51, 852-60	7.5	21
87	Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial. <i>Lancet Oncology</i> , 2015 , 16, 550-60	21.7	79
86	Melanoma early detection and awareness: how countries developing melanoma awareness programs could benefit from melanoma-proficient countries. <i>American Journal of Therapeutics</i> , 2015 , 22, 37-43	1	7
85	Treatment algorithms in stage IV melanoma. <i>American Journal of Therapeutics</i> , 2015 , 22, 61-7	1	9
84	Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. <i>Lancet Oncology</i> , 2015 , 16, 1389-98	21.7	162
83	Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone. <i>Annals of Surgical Oncology</i> , 2015 , 22, 2860-8	3.1	103
82	Improved overall survival in melanoma with combined dabrafenib and trametinib. <i>New England Journal of Medicine</i> , 2015 , 372, 30-9	59.2	1723

81	Etoposide and carbo-or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: a large retrospective study. <i>Pediatric Blood and Cancer</i> , 2015 , 62, 40-4	3	14
80	Denosumab for treating giant cell tumor of bone. <i>Expert Opinion on Orphan Drugs</i> , 2015 , 3, 1219-1229	1.1	5
79	The long-term results and prognostic significance of cutaneous melanoma surgery using sentinel node biopsy with triple technique. <i>World Journal of Surgical Oncology</i> , 2015 , 13, 299	3.4	7
78	The outcomes of Polish patients with advanced BRAF-positive melanoma treated with vemurafenib in a safety clinical trial. <i>Wspolczesna Onkologia</i> , 2015 , 19, 280-3	1	2
77	Trametinib: a MEK inhibitor for management of metastatic melanoma. <i>OncoTargets and Therapy</i> , 2015 , 8, 2251-9	4.4	63
76	Serum markers in early-stage and locally advanced melanoma. <i>Tumor Biology</i> , 2015 , 36, 8277-85	2.9	26
75	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015 , 373, 23-34	59.2	5047
74	Current treatment options for dermatofibrosarcoma protuberans. <i>Expert Review of Anticancer Therapy</i> , 2015 , 15, 901-9	3.5	24
73	Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4216-83	2.2	102
72	Genomic index predicts clinical outcome of intermediate-risk gastrointestinal stromal tumors, providing a new inclusion criterion for imatinib adjuvant therapy. <i>European Journal of Cancer</i> , 2015 , 51, 75-83	7.5	15
71	Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib. <i>Cancer</i> , 2015 , 121, 1405-13	6.4	67
70	Comparison between two widely used laboratory methods in BRAF V600 mutation detection in a large cohort of clinical samples of cutaneous melanoma metastases to the lymph nodes. <i>International Journal of Clinical and Experimental Pathology</i> , 2015 , 8, 8487-93	1.4	8
69	Standardy leczenia i wieniwego w onkologii. <i>Nowotwory</i> , 2015 , 65, 320-337	0.5	2
68	Follow-up in melanoma patients. <i>Memo - Magazine of European Medical Oncology</i> , 2014 , 7, 83-86	0.3	4
67	Gene expression profiling of peripheral blood cells: new insights into Ewing sarcoma biology and clinical applications. <i>Medical Oncology</i> , 2014 , 31, 109	3.7	17
66	Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary site. <i>Annals of Surgical Oncology</i> , 2014 , 21, 4317-23	3.1	15
65	Follow-up in soft tissue sarcomas. <i>Memo - Magazine of European Medical Oncology</i> , 2014 , 7, 92-96	0.3	17
64	Adherence to imatinib therapy in patients with gastrointestinal stromal tumors. <i>Cancer Treatment Reviews</i> , 2014 , 40, 242-7	14.4	26

63	Metastatic potential is determined early in synovial sarcoma development and reflected by tumor molecular features. <i>International Journal of Biochemistry and Cell Biology</i> , 2014 , 53, 505-13	5.6	30
62	Molecular alterations in clinical stage III cutaneous melanoma: Correlation with clinicopathological features and patient outcome. <i>Oncology Letters</i> , 2014 , 8, 47-54	2.6	29
61	Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC). <i>Current Signal Transduction Therapy</i> , 2014 , 8, 218-228	0.8	56
60	The outcome of targeted therapy in advanced gastrointestinal stromal tumors (GIST) with non-exon 11 KIT mutations. <i>Polski Przegląd Chirurgiczny</i> , 2014 , 86, 325-32	0.6	2
59	Dabrafenib for the treatment of BRAF V600-positive melanoma: a safety evaluation. <i>Expert Opinion on Drug Safety</i> , 2014 , 13, 1249-58	4.1	14
58	Frequent mono-allelic loss associated with deficient PTEN expression in imatinib-resistant gastrointestinal stromal tumors. <i>Modern Pathology</i> , 2014 , 27, 1510-20	9.8	22
57	Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a european multicenter analysis based on ConticaGIST. <i>Clinical Cancer Research</i> , 2014 , 20, 6105-16	12.9	96
56	Genetics of rare mesenchymal tumors: implications for targeted treatment in DFSP, ASPS, CCS, GCTB and PEComa. <i>International Journal of Biochemistry and Cell Biology</i> , 2014 , 53, 466-74	5.6	9
55	Polish clinical practice guideline on hyperthermic intraperitoneal chemotherapy (HIPEC) with cytoreductive surgery in peritoneal malignancy treatment. <i>Current Gynecologic Oncology</i> , 2014 , 12, 86-97		4
54	Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. <i>Lancet Oncology, The</i> , 2013 , 14, 901-8	21.7	389
53	Extended adjuvant therapy with imatinib in patients with gastrointestinal stromal tumors : recommendations for patient selection, risk assessment, and molecular response monitoring. <i>Molecular Diagnosis and Therapy</i> , 2013 , 17, 9-19	4.5	10
52	Surgery quality and tumor status impact on survival and local control of resectable liposarcomas of extremities or the trunk wall. <i>Clinical Orthopaedics and Related Research</i> , 2013 , 471, 860-70	2.2	11
51	Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience. <i>Annals of Surgical Oncology</i> , 2013 , 20, 2937-43	3.1	149
50	What are the current outcomes of advanced gastrointestinal stromal tumors: who are the long-term survivors treated initially with imatinib?. <i>Medical Oncology</i> , 2013 , 30, 765	3.7	17
49	Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2013 , 381, 295-302	40	908
48	Efficacy and economic value of adjuvant imatinib for gastrointestinal stromal tumors. <i>Oncologist</i> , 2013 , 18, 689-96	5.7	8
47	Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3831-7	2.2	70
46	Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis. <i>Wspolczesna Onkologia</i> , 2013 , 17, 257-62	1	8

45	Effective treatment of recurrent, advanced dermatofibrosarcoma protuberans by electrochemotherapy. <i>European Journal of Dermatology</i> , 2013 , 23, 260-1	0.8	6
44	Small bowel tumors detected and missed during capsule endoscopy: single center experience. <i>World Journal of Gastroenterology</i> , 2013 , 19, 9043-8	5.6	46
43	Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib. <i>Annals of Surgical Oncology</i> , 2012 , 19, 1551-9	3.1	53
42	Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. <i>Lancet, The</i> , 2012 , 380, 358-65	4.0	2233
41	Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. <i>Lancet Oncology, The</i> , 2012 , 13, 265-74	21.7	601
40	Recurrent and novel SS18-SSX fusion transcripts in synovial sarcoma: description of three new cases. <i>Tumor Biology</i> , 2012 , 33, 2245-53	2.9	23
39	Technical considerations in surgery for retroperitoneal sarcomas: position paper from E-Surge, a master class in sarcoma surgery, and EORTC-STBSG. <i>Annals of Surgical Oncology</i> , 2012 , 19, 2981-91	3.1	146
38	Adjuvant vaccination with melanoma antigen-pulsed dendritic cells in stage III melanoma patients. <i>Medical Oncology</i> , 2012 , 29, 2966-77	3.7	17
37	The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study. <i>BMC Cancer</i> , 2012 , 12, 107	4.8	57
36	Results of systemic treatment of cutaneous melanoma in inoperable stage III and IV. <i>Wspolczesna Onkologia</i> , 2012 , 16, 532-45	1	6
35	Improved survival with MEK inhibition in BRAF-mutated melanoma. <i>New England Journal of Medicine</i> , 2012 , 367, 107-14	59.2	1634
34	Downstream and intermediate interactions of synovial sarcoma-associated fusion oncoproteins and their implication for targeted therapy. <i>Sarcoma</i> , 2012 , 2012, 249219	3.1	17
33	Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. <i>Clinical Cancer Research</i> , 2012 , 18, 4458-64	12.9	143
32	Gene Signatures in Gastrointestinal Stromal Tumors 2012 , 35-50		
31	Trabectedin in patients with pre-treated advanced soft tissue sarcoma: a retrospective single center analysis. <i>Wspolczesna Onkologia</i> , 2011 , 6, 367-371	1	1
30	Advances in molecular characterization and targeted therapy in dermatofibrosarcoma protuberans. <i>Sarcoma</i> , 2011 , 2011, 959132	3.1	29
29	Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. <i>American Journal of Surgical Pathology</i> , 2011 , 35, 1712-21	6.7	272
28	Clinical utility of the new American Joint Committee on Cancer staging system for gastrointestinal stromal tumors: current overall survival after primary tumor resection. <i>Cancer</i> , 2011 , 117, 4916-24	6.4	41

27	Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2206-14	2.2	164
26	Melanoma without a detectable primary site with metastases to lymph nodes. <i>Dermatologic Surgery</i> , 2010 , 36, 868-76	1.7	34
25	Cutaneous melanoma with nodal metastases in elderly people. <i>International Journal of Dermatology</i> , 2010 , 49, 907-13	1.7	10
24	Surgery of primary melanomas. <i>Cancers</i> , 2010 , 2, 824-41	6.6	10
23	Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1772-9	2.2	297
22	Multimarker reverse transcriptase-polymerase chain reaction assay in lymphatic drainage and sentinel node tumor burden. <i>Annals of Surgical Oncology</i> , 2010 , 17, 3314-23	3.1	7
21	The megavoltage radiation therapy in treatment of patients with advanced or difficult giant cell tumors of bone. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010 , 78, 494-8	4	52
20	Functional features of gene expression profiles differentiating gastrointestinal stromal tumours according to KIT mutations and expression. <i>BMC Cancer</i> , 2009 , 9, 413	4.8	20
19	Other targetable sarcomas. <i>Seminars in Oncology</i> , 2009 , 36, 358-71	5.5	12
18	Emergency surgery in the era of molecular treatment of solid tumours. <i>Lancet Oncology</i> , 2009 , 10, 157-63	21.7	42
17	Gastrointestinal stromal tumors: key to diagnosis and choice of therapy. <i>Molecular Diagnosis and Therapy</i> , 2008 , 12, 131-43	4.5	25
16	Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes. <i>Annals of Surgery</i> , 2008 , 248, 949-55	7.8	193
15	Molecular staging by multimarker reverse transcriptase-polymerase chain reaction assay of lymphatic drainage and blood from melanoma patients after lymph node dissection. <i>Melanoma Research</i> , 2008 , 18, 246-52	3.3	11
14	Rectal gastrointestinal stromal tumors associated with a novel germline KIT mutation. <i>International Journal of Cancer</i> , 2008 , 122, 2160-4	7.5	27
13	The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3). <i>Annals of Surgical Oncology</i> , 2008 , 15, 2223-34	3.1	49
12	Developments in targeted therapy of advanced gastrointestinal stromal tumors. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2008 , 3, 88-99	2.6	21
11	Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors. <i>Laboratory Investigation</i> , 2007 , 87, 1029-41	5.9	83
10	Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. <i>Annals of Surgical Oncology</i> , 2007 , 14, 2018-27	3.1	196

9	Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs). <i>Journal of Cancer Research and Clinical Oncology</i> , 2007 , 133, 589-97	4.9	27
8	Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. <i>Journal of Surgical Oncology</i> , 2006 , 93, 304-11	2.8	141
7	Surgery combined with intraoperative brachytherapy in the treatment of retroperitoneal sarcomas. <i>Annals of Surgical Oncology</i> , 2006 , 13, 245-52	3.1	44
6	Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma. <i>Annals of Surgical Oncology</i> , 2006 , 13, 1655-63	3.1	84
5	Increased cancer risk of heterozygotes with NBS1 germline mutations in Poland. <i>International Journal of Cancer</i> , 2004 , 111, 67-71	7.5	99
4	Detection of melanoma cells in the lymphatic drainage after lymph node dissection in melanoma patients by using two-marker reverse transcriptase-polymerase chain reaction assay. <i>Annals of Surgical Oncology</i> , 2004 , 11, 988-97	3.1	12
3	Sentinel lymph node biopsy in melanoma patients with clinically negative regional lymph nodes--one institution's experience. <i>Melanoma Research</i> , 2003 , 13, 35-43	3.3	66
2	Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis. <i>Journal of Surgical Oncology</i> , 2003 , 84, 151-9	2.8	91
1	Prognostic value of multiple reverse transcription-PCR tyrosinase testing for circulating neoplastic cells in malignant melanoma. <i>Clinical Chemistry</i> , 2003 , 49, 1450-7	5.5	28